about
Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary resultsMetformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro.Metformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro[Peripartum cardiomyopathy, acute autoimmune pancreatitis and periadipose tissue inflammation - autoimmune reaction?].[Report on the Euro Cardiologic Magnetic Resonance Working Group annual meeting, May 22-24 in Lisbon, Portugal, 2008].Corrigendum to "Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner" [Pharmacological Reports 68 (2016) 329-337].Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.[Role of perfusion imaging in computed tomography in diagnostics of cerebral gliomas].Short-term antihypertensive therapy lowers the C-reactive protein level.[Markers of inflammatory process in stable and unstable coronary artery disease]Extralipid effects of micronized fenofibrate in dyslipidemic patients[The role of cardiovascular magnetic resonance imaging in dilated cardiomyopathy]Assessment of left ventricular function with computed tomography and magnetic resonance in patients with low ejection fraction scheduled for coronary artery bypass grafting: a preliminary study[Right atrial tumour and right ventricular failure - diagnostic role of echocardiography and cardiovascular magnetic resonance]Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus
P50
Q34270969-5776836E-8743-4F4D-BFD8-A5B651C854D0Q36640261-C1E98214-80AA-47B0-85BC-AB6C810C2FEBQ42316779-9C2F5E9A-649E-4DC4-8CF2-278D2A791B3FQ45388657-815A8FD7-7BBF-4ACC-80CD-7744548DD735Q51125349-F3363F59-6BAD-436A-9F5E-45A8992A62CFQ51145644-6B058A32-3107-4301-964D-5C620CD55932Q52882844-41C672A0-7B3F-4E64-8A56-4A1F4CFB3EA7Q53552808-F4F5ED90-EC9A-4EED-9348-6DCF84ECE8FDQ53654878-97ABD699-4387-457A-B9AB-A23B30CAE9CDQ79153435-9C3A1291-F9F4-4134-BFA6-F2B397CE3425Q79330799-0D9A4B03-747C-4325-9DBD-7090378478D7Q83367363-AA995C36-EAB5-4DD8-9B27-9283595E56E2Q84488828-16C9FA15-D104-4CA3-BC6D-E5E97CE9EE27Q85241382-F28EEBF9-3BB4-43F1-992F-FC3C53079BC1Q86476765-AECD2379-D45E-4B81-84D6-82CB5E520ADA
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
Margin Basiak
@en
Margin Basiak
@nl
type
label
Margin Basiak
@en
Margin Basiak
@nl
prefLabel
Margin Basiak
@en
Margin Basiak
@nl
P106
P31
P496
0000-0003-0674-5612